CANDEL THERAPEUTICS I

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

13 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

05 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

12 Dec 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409

28 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

09 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

04 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

03 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

18 Oct 2023 10:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting

27 Sep 2023 08:40:53 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

26 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

10 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference

02 Aug 2023 07:00:29 By Nasdaq GlobeNewswire

Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024

13 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors

08 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

05 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

19 May 2023 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

11 May 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO

02 May 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer

17 Apr 2023 07:00:00 By Nasdaq GlobeNewswire